Standard BioTools
LAB
99 hedge funds and large institutions have $422M invested in Standard BioTools in 2018 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 11 closing their positions.
1,594% more call options, than puts
Call options by funds: $288K | Put options by funds: $17K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
182% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 11
117% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 18
45% more capital invested
Capital invested by funds: $291M → $422M (+$131M)
25% more funds holding
Funds holding: 79 → 99 (+20)
2.26% more ownership
Funds ownership: 99.23% → 101.5% (+2.3%)
Top Buyers
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$18M |
| 2 |
Neuberger Berman Group
New York
|
+$7.24M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$6.93M |
| 4 |
RI
RTW Investments
New York
|
+$6.89M |
| 5 |
Primecap Management
Pasadena,
California
|
+$6.35M |
Top Sellers
LAB Hedge Fund Activity: Q4 2018 in Review
99 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q4 2018, worth a combined $422M — up 45% from $291M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new LAB positions and 11 closed out — a net gain of 20 holders — while 39 added to existing stakes and 18 trimmed.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $18M. The largest seller was OrbiMed, exiting entirely with an estimated $8.07M sold.
- 99 institutional investors held Standard BioTools (LAB) as of Q4 2018, up from 79 in Q3 2018.
- Funds reported $422M of Standard BioTools stock for Q4 2018, up 45% quarter-over-quarter.
- 31 funds opened new Standard BioTools positions in Q4 2018 and 11 closed out, a net change of +20 holders.
- The largest Standard BioTools buyer in Q4 2018 was Driehaus Capital Management, an estimated $18M added.
- The largest Standard BioTools seller in Q4 2018 was OrbiMed, an estimated $8.07M sold.
Based on aggregated 13F filings for Q4 2018.